AMDX-2011P

N/A

Report date: 2026/02/14 20:00:22

NMEFirst In Class

Base Information

Drug NameAMDX-2011P

Drug Alias NameAlpha synucleinopathies targeted small molecule retinal tracer (Amydis)TAR DNA binding protein 43 targeted small molecule retinal tracer (Amydis)AMDX-2011PAMDX2011P

ClassificationDiagnostic agent (In vivo)Small molecules > Heterocyclic drugs

Mechanisms of ActionSynuclein alpha modulatorsTAR DNA binding protein 43 modulators

TargetsSynuclein alphaTAR DNA binding protein 43

Therapy Area/IndicationsGlaucoma, Open-AngleAmyotrophic Lateral SclerosisAlzheimer Disease +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAmydis Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmydis Inc

Inactive CompaniesN/A

Active IndicationsGlaucoma, Open-AngleAmyotrophic Lateral SclerosisAlzheimer Disease +[5]

Inactive IndicationsN/A

Other Information

ATC CodeN/A